Scaling Monoclonal Antibody Production from 3,000L to 20,000L: Challenges, Strategies, & COGs Analysis

As monoclonal antibody (mAb) therapeutics continue to expand across oncology, immunology, and rare disease applications, manufacturers face increasing pressure to deliver large-scale commercial supply while maintaining robust process consistency, product quality, and cost efficiency. The transition from clinical-scale production to commercial manufacturing introduces significant technical and operational challenges, particularly in maintaining process performance and product comparability during scale-up. Successful implementation of high-volume manufacturing platforms is therefore critical to meeting growing global demand for biologics while enabling sustainable cost structures.

In this whitepaper, Rubin Jiang, Senior Director of MSAT at Altruist Biologics, presents a successful scale-up of a mAb manufacturing process from 3,000L to 20,000L using a stainless steel manufacturing system, highlighting key upstream optimization strategies, downstream process considerations, and cost-of-goods (CoG) reduction approaches to ultimately provide a scalable framework for industrial biomanufacturing operations seeking to improve supply reliability, operational efficiency, and global market competitiveness.